



Cardiovascular Risk Factors in Offspring of Preeclamptic Pregnancies—Systematic Review and Meta-Analysis

Prabha H. Andraweera, MBBS, PhD, and Zohra S. Lassi, PhD

Objective To evaluate evidence for increased cardiovascular disease (CVD) risk factors in children exposed to preeclampsia in utero.

Study design PubMed, the Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and EMBASE electronic databases were searched with an end of search date of June 4, 2018. Prospective and retrospective studies that compared CVD risk factors in those exposed to preeclampsia in utero with controls were eligible. Information was extracted on established CVD risk factors, including blood pressure, lipid profile, blood glucose, fasting insulin, body mass index, and endothelial/microvascular function.

Results Thirty-six studies provided cumulated data on 53 029 individuals. In utero exposure to preeclampsia was associated with 5.17 mm Hg (95% CI 1.60–8.73) greater mean systolic, 4.06 mm Hg (95% CI 0.67–7.44) greater mean diastolic blood pressure, and 0.36 kg/m² (95% CI 0.04–0.68) greater mean body mass index during childhood or young adulthood. No significant association was seen between exposure to preeclampsia in utero and other CVD risk factors.

Conclusions Offspring of preeclamptic pregnancies demonstrate risk factors for CVD during childhood and young adult life. Early blood pressure screening of children born after preeclamptic pregnancies may identify those that require interventions or preventive strategies to reduce later life CVD risk. (*J Pediatr* 2019;208:104-13).

Cardiovascular disease (CVD) is a major global health burden that results in the greatest number of deaths worldwide. The World Health Organization estimates that 17.6 million people died from CVD in 2012, accounting for 31.4% of global mortality.¹ Research shows a strong link between preeclampsia and CVD.² Preeclampsia is a pregnancy complication that affects 2%–8% of pregnancies and is a leading cause of maternal and infant morbidity and mortality.³ Over the last decade, an accumulating body of research demonstrated that women who develop preeclampsia are at increased risk of CVD in later life.² A systematic review and meta-analysis that has assessed studies published until the end of 2012 shows that women who develop preeclampsia are at approximately twice the risk of developing or dying from overall CVD, ischemic heart disease, and stroke.² The likelihood of developing risk factors for CVD including hypertension and diabetes also is increased among women who develop preeclampsia compared with women who have normotensive pregnancies.² The bulk of evidence linking preeclampsia with CVD has resulted in preeclampsia being recognized by the American Heart Association as a female-specific cardiovascular risk factor.⁴

Emerging evidence also suggests that offspring of preeclamptic pregnancies also may be at increased risk of CVD in adult life. A long-term follow-up study reports that offspring of preeclamptic pregnancies are at twice the risk of stroke compared with offspring of normotensive pregnancies.⁵ Davis et al performed a systematic review of studies published until mid-2011 that assessed CVD risk factors in offspring of preeclamptic pregnancies and reported that young offspring of preeclamptic pregnancies have increased blood pressure and body mass index (BMI).⁶ At the time of the aforementioned review, there were not sufficient publications to perform meta-analyses on other conventional risk factors, including blood glucose and lipids. The aim of this study was to conduct an updated systematic review of all relevant studies published until June 2018 to assess risk factors for CVD, including systolic and diastolic blood pressure, BMI, blood glucose, lipids, and vascular function among those exposed to preeclampsia in utero.

| | |
|-----|--------------------------|
| BMI | Body mass index |
| CVD | Cardiovascular disease |
| DBP | Diastolic blood pressure |
| HDL | High-density lipoprotein |
| LDL | Low-density lipoprotein |
| SBP | Systolic blood pressure |
| SMD | Standard mean difference |

From the Adelaide Medical School and The Robinson Research Institute, The University of Adelaide, Adelaide, Australia

P.A. is supported by a National Health and Medical Research Council (NHMRC) Australia Peter Doherty BioMedical Postdoctoral Fellowship (APP1090778). Z.L. is supported by a NHMRC Australia Public Health Postdoctoral Fellowship (APP1141382).

0022-3476/\$ - see front matter. © 2019 Elsevier Inc. All rights reserved.
<https://doi.org/10.1016/j.jpeds.2018.12.008>

Methods

The review protocol is registered in PROSPERO (CRD42017074322). The following electronic databases were searched: PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and EMBASE with an end of search date of August 31, 2017. Subsequently, we conducted an updated search to include all relevant articles published until June 4, 2018. Our search strategy included terms such as “preeclampsia,” “pre-eclampsia,” “toxaemia,” “toxemia,” “gestation* hypertension,” “pregnancy induced hypertension,” and “eclampsia” AND “children,” “offspring,” “neonate,” “infant” AND “pregnan*,” “mother,” “women,” and “woman”; the search was limited to English and humans. The PRISMA guidelines were followed in conducting this systematic review.⁷ Prospective and retrospective studies comparing CVD risk factors in those exposed to preeclampsia in utero with controls (either normotensive pregnancies or nonhypertensive pregnancies) were included. References of identified studies also were searched. We included studies that defined preeclampsia using the current International Society for the Study of Hypertension in Pregnancy guidelines.⁸ However, as diagnostic criteria have changed over time, studies that used previous standard definitions of preeclampsia, including de novo onset of hypertension and proteinuria, also were included.⁹ The definitions used in the individual studies are detailed in **Table I**. We excluded studies in which gestational hypertension and preeclampsia were considered together or when these 2 conditions were not distinguished. Studies were included if they reported the following outcomes in offspring: blood pressure (systolic or diastolic), BMI, lipid levels, blood glucose, insulin levels, and endothelial/microvascular function. All identified studies were sifted for relevance by 2 authors. Data were extracted from eligible studies by one author and cross-checked for accuracy by the second author. Discrepancies were resolved by discussion. The methodologic quality of each study was assessed independently by 2 authors using the Newcastle–Ottawa Quality Assessment Scale.⁴⁵

The meta-analyses were conducted using Review Manager (RevMan) 5.3, with Mantel–Haenszel random-effects models. For each outcome measure, mean and SD were used in meta-analyses. The standard mean difference (SMD) or mean difference and the 95% CI were calculated. When mean and SD were not reported, the results were extracted as reported (ie, mean \pm SEM, mean and CIs or range) and detailed in **Table II** (available at www.jpeds.com). Substantial heterogeneity was considered when I^2 statistic exceeded 50%, and the χ^2 P value was $<.1$. To assess publication bias, funnel plots were used for the primary outcomes.

Results

A total of 5162 articles were identified by the search and a further 15 from bibliographic search, of which 85 were

eligible for full-text review (**Figure 1**). Of these, 36 were included in the review and 24 were included in the meta-analysis. The reasons for excluding 49 studies are detailed in **Figure 1**. Of the studies included in the meta-analyses, 8.3% were of high quality (scored 7-8), 75% were of moderate quality (scored 4-6), and 8.3% were of low quality (scored 1-3) as assessed by the Newcastle–Ottawa Scale (**Table II**).

Systolic Blood Pressure

Systolic blood pressure (SBP) data were available from 20 studies. Of these, 15 were included in the meta-analyses providing data on 53 029 individuals, of whom 1599 were exposed to preeclampsia in utero (**Figure 2, A**).^{16,18,20-22,24-27,34,35,37,39,41,46-48} Quantitative summary measures obtained by meta-analysis demonstrate that offspring of preeclamptic pregnancies have 5.17 mm Hg (95% CI 1.60-8.73) greater SBP compared with offspring of control pregnancies (**Figure 2, A**). Of the 5 studies that were not included in the meta-analysis, 3 report that offspring of preeclamptic pregnancies have greater SBP compared with controls,^{30,38,43} and 1 reports that offspring of term preeclamptic pregnancies have greater mean SBP compared with controls but no significant difference between offspring of preterm preeclamptic pregnancies compared with controls (**Table III**; available at www.jpeds.com).¹² The other study reports that those born after early preeclampsia (defined as onset <34 weeks) have greater SBP compared with those born after late preeclampsia²⁸ (**Table III**).

Diastolic Blood Pressure

Diastolic blood pressure (DBP) data were available from 18 studies. Of these, 14 were included in the meta-analysis, providing data on 52 993 individuals, of whom 1583 were exposed to preeclampsia in utero (**Figure 2, B**).^{15,16,18,20-22,26,27,31,34,35,37,39,41} Quantitative summary measures obtained by meta-analysis demonstrate that offspring of preeclamptic pregnancies have 4.06 mm Hg (95% CI 0.67-7.44) greater DBP compared with controls (**Figure 2, B**). The 3 studies that were not included in the meta-analysis also report greater DBP among offspring of preeclamptic pregnancies compared with controls (**Table III**).^{12,30,38}

BMI

BMI data were available from 17 studies. Of these, 13 were included in the meta-analysis, providing data on 53 293 individuals, of whom 1752 were exposed to preeclampsia in utero (**Figure 3**). Quantitative summary measures obtained by meta-analysis demonstrate that offspring of preeclamptic pregnancies have 0.36 kg/m² (95% CI 0.04-0.68) greater BMI compared with controls (**Figure 3**).^{5,16,18,24-27,31,37,39,41,42,46} The 4 studies that were not included in the meta-analysis reported greater BMI among offspring of preeclamptic pregnancies compared with controls (**Table III**).^{12,30,40}

Table I. Characteristics of the included studies

| Study | Definition of preeclampsia SBP/DBP; proteinuria | Exposed to preeclampsia/controls | Birth weight cases/ controls, g | Gestational age cases/ controls, wk | Follow- up, y | Outcome measure considered |
|-------------------------------------|---|--|---|---|------------------|---|
| Akcakus et al, 2010 ¹⁰ | >140/90, severe >160/110; 300 mg/24 h | 30/30/30 | 1817/1693/1762 | 32.4/32.4/31.5 | 0 | Lipids |
| Alsnes et al, 2014 ¹¹ | DBP ≥90 + increase of DBP >25; >0.3 g/L (1+) | 228/383 | Not reported | Not reported | 11 | Lipids/glucose |
| Alsnes et al, 2017 ¹² | ≥140/90; 0.3 g/24 h (1+) | Term PE 343/preterm PE 27/ controls 15072 | Term PE 3399/ Preterm PE 2094/No PE 3535 | Term PE 100% ≥37 wk, preterm PE 25.9% <34 wk/ 74.1% 34-36 wk, No PE 0.9% <34 wk, 3% 34-36 wk, 96.1% ≥37 wk | 28-29 | SBP/DBP/BMI/lipids |
| Catarino et al, 2008 ¹³ | DBP >110 or >90 on repeated measures; 0.3 g/24 h (1+) | 46/42 | 2600/3400 | 37/38.5 | 0 | Lipids |
| Davidge et al, 1996 ¹⁴ | >140/90 or rise >30/15; 0.5 g/24 h (2+) | 17/17 | 2920/3500 | 39.0/39.9 | 0 | Endothelial function |
| Davis et al, 2015 ¹⁵ | >140/90; 0.3 g/24 h (2+) | 46/899 | 2658/3363 | 36.1/39.5 | 20 | SBP/DBP/BMI/lipids/glucose/insulin |
| Fraser et al, 2013 ¹⁶ | >140/90 × ≥2; 1+ | 53/2404 | 3217/3467 | 39.2/39.6 | 17 | SBP/DBP/BMI/lipids/glucose/insulin |
| Fugelseth et al, 2011 ¹⁷ | >140/90 × ≥2; 1+ | 25/15 | 1740/3500 | 32.3/38.6 | 5-8 | Myocardial function |
| Geelhoed et al, 2010 ¹⁸ | >139/89 × ≥2; 1+ | 205/5345 | 3103/3446 | Not reported | 9 | SBP/DBP/BMI |
| Herzog et al, 2017 ¹⁹ | >140/90; PCR ≥ 30 | 15 EPE, 15 LPE/164 | 1185 EPE, 3200 LPE/3560 | 30.7 EPE, 37.4 LPE/39.6 | 0 | Placental and umbilical cord vasculature |
| Hiller et al, 2007 ²⁰ | DBP >110 or 2× DBP >90; 300 mg/ 24 h or 2× 2++ protein | 10 and 78 | Not reported | Not reported | 4-7 | SBP/DBP |
| Howlader et al, 2009 ²¹ | >140/90 or rise >30/15; 3000 mg/24 h | 15/20 | 1750/2570 | 33.25/36.9 | 0 | SBP/DBP/lipids/markers of oxidative stress |
| Jayet et al, 2010 ²² | >140/90 or rise >30/15; Consecutive dipstick tests proteinuria | 48 and 90 | 2843 and 3244 | >37 and <42 | 14 | SBP/DBP/BMI/vascular dysfunction |
| Kajantie et al, 2009 ⁵ | >140/90; 1+ | Nonsevere 120, severe 164/4271 | Nonsevere 3216, severe 2894/3435 | Nonsevere 39.6, severe 39.3/40.0 | Not reported | BMI |
| Kajantie et al, 2017 ²³ | >140/90; 1+ | Nonsevere 97, severe 134/3524 | Nonsevere 3227, severe 2881/3430 | Nonsevere 39.7, severe 39.3/ 40.0 | Not reported | Type 2 diabetes mellitus |
| Kvehaugen et al, 2010 ²⁴ | >140/90 × ≥2; ≥ 1+ on ≥2 samples | 23 and 17 | 1740 and 3526 | 32.3 and 38.6 | 5-8 | SBP/DBP/BMI |
| Kvehaugen et al, 2011 ²⁵ | >140/90 × ≥2; ≥ 1+ on ≥2 samples | 26/15 | Not reported | Not reported | 5-8 | Lipids/endothelial function |
| Lawlor et al, 2012 ²⁶ | >139/>89; 1+ | 143 and 5367 | 3042 and 3443 | 37.6 and 39.5 | 9-10 | SBP/DBP/BMI/lipids |
| Lazdam et al, 2010 ²⁷ | >140/90; 2+ | 16 and 38 | 1323/? | 30.93/>37 | 20-30 | SBP/DBP/BMI/lipids/glucose/insulin |
| Lazdam et al, 2012 ²⁸ | >140/90; 2+ | 90/50 | Not reported | Not reported | 6-13 | SBP |
| Libby et al, 2007 ²⁹ | DBP≥90 × 2; albuminuria | 700/7948 | 3290/3320 | 40/40 | 45-49 | Type 2 diabetes mellitus |
| Miettola et al, 2013 ³⁰ | >140/90; ≥0.3 g | 197/5045 | 3378/3581 | 38.8/39.5 | 16 | SBP/DBP/BMI/lipids/glucose/insulin |
| Oglaend et al, 2009 ³¹ | > in DBP to >90; 1+ | 181/356 | Not reported | 37.6/40.1 | 10-12 | SBP/DBP |
| Ogland et al, 2009 ³² | > in DBP to >90; 1+ | F: 91/194, M: 92/166 | F: 3010/3510, M: 2970/3600 | F: 37.5/39.7, M: 37.2/39.7 | 10-12 | BMI |
| Ophir et al, 2006 ³³ | >140/90; >300 mg/24 h | 36/35 | 2883/3274 | 37.7/38.8 | 0 | Lipids |
| Palti et al, 1989 ³⁴ | >140/90 or rise >30/15; Edema and proteinuria | 94 and 94 | 12.7% LBW cases/4.2% LBW controls | 22% cases <37/ 4.3% controls <37 | 6 | SBP/DBP |
| Reveret et al, 2015 ³⁵ | >140/90; >300 mg/24 h | 72/83 | 1561/1856 | 31.3/31.3 | 0 | SBP/DBP |
| Rodie et al, 2004 ³⁶ | DBP >110 or >90 repeatedly; ≥0.3 g/24 h | 41/81 | 2510/3770 | 36.5/40 | 0 | Lipids |
| Seidman et al, 1991 ³⁷ | 1952 American Committee on Maternal Welfare Definition | 428/33 117 | M: 3175/3338, F: 3009/3215 | Not reported | 17 | SBP/DBP/BMI |

(continued)

Table I. Continued

| Study | Definition of preeclampsia SBP/DBP; proteinuria | Exposed to preeclampsia/controls | Birth weight cases/ controls, g | Gestational age cases/ controls, wk | Follow- up, y | Outcome measure considered |
|------------------------------------|--|-------------------------------------|------------------------------------|--|------------------|------------------------------------|
| Staley et al, 2015 ³⁸ | >140/90; 1+ | 161/6716 | 3029/3443 | 38.0/39.5 | 7 | SBP/DBP |
| Tenhola et al, 2003 ³⁹ | >140/90 or rise >30/15; >300 mg/24 h | 60/60 | 2622/2868 | 36.6/36.7 | 12 | SBP/DBP/BMI/lipids/glucose/insulin |
| Timpka et al, 2016 ⁴⁰ | >140/90; proteinuria on dipstick | 42/1260 | 3000/3440 | 38.5/40.0 | 17 | BMI/cardiac structure and function |
| Vatten et al, 2003 ⁴¹ | >140/90 or rise >30/15; >300 mg/24 h | 220/3853 | 3421/3485 | 40.3/40.6 | 13-19 | SBP/DBP/BMI |
| Washburn et al, 2013 ⁴² | >140/90 or rise >30/15; >300 mg/24 h | 51/121 | 1059/1033 | 29.0/27.1 | 14 | BMI |
| Wen et al, 2011 ⁴³ | American Committee on Maternal Welfare Definition | 5359/25102 | Not reported | Not reported | 7 | BMI/SBP |
| Yavuz, et al 2006 ⁴⁴ | >140/90; >300 mg/24 h | 7 and 26 | 2640/3500 | 38/39 | 0 | Lipids |

EPE, Early preeclampsia; F, female; LBW, low birth weight; LPE, Late preeclampsia; M, male; PCR, protein creatinine ratio; PE, preeclampsia.

Total Cholesterol

Total cholesterol data were available from 12 studies, of which 5 reported on cord blood and 7 on offspring blood. The meta-analyses on studies on cord blood (n = 3) showed no difference in total cholesterol between offspring of preeclamptic pregnancies compared with controls (SMD 1.23, 95% CI -0.59 to 3.05, **Figure 4** [available at www.jpeds.com]).^{21,33,36} The 2 studies that were not included in the meta-analysis also showed no significant difference in total cholesterol between the 2 groups.^{13,44} Of the 7 studies on offspring blood, 5 were included in the meta-analysis providing data on 3798 individuals, of whom 396 were exposed to preeclampsia in utero (**Figure 4**). Quantitative summary measures obtained by meta-analysis demonstrate no significant difference in total cholesterol levels in offspring of preeclamptic pregnancies and controls (SMD 0.47, 95% CI 0.21-1.16, **Figure 4**).^{11,15,16,27,39} Of the 2 studies that were not included in the meta-analysis, one reports greater total cholesterol²⁵ and the other reports no significant difference in total cholesterol between the 2 groups (**Table III**).³⁰

Low-Density Lipoprotein Cholesterol

Low-density lipoprotein (LDL) cholesterol data were available from 12 studies, which included 5 on cord blood and 7 on offspring blood. The 3 studies on cord blood that were included in the meta-analysis report an increase in LDL cholesterol in offspring of preeclamptic pregnancies compared with controls with the quantitative analysis demonstrating a 0.30 mean difference (95% CI 0.29-4.31, **Figure 5** [available at www.jpeds.com]).^{21,33,36} The 2 studies that were not included in the meta-analysis report no significant difference between the 2 groups (**Table III**).^{13,44} Of the 7 studies on offspring blood, 5 were included in the meta-analysis, providing data on 3465 individuals, of whom 258 were exposed to preeclampsia in utero (**Figure 5**). Quantitative summary measures obtained by meta-analysis demonstrate no difference in LDL cholesterol between offspring of preeclamptic pregnancies and controls (SMD 0.12, 95% CI -0.09 to 0.34, **Figure 5**).^{15,16,27,28,39} Both studies that were not included in the meta-analysis report that there is no difference in LDL cholesterol between offspring of preeclamptic pregnancies and controls (**Table III**).^{25,30}

High-Density Lipoprotein Cholesterol

High-density lipoprotein (HDL) cholesterol data were available from 14 studies, which included 5 on cord blood and 9 on offspring blood. The 5 studies on cord blood could not be included in the meta-analysis. Of these, 3 reported a significant reduction^{10,13,21} and 2 reported no significant difference^{36,44} in cord blood HDL between offspring of preeclamptic pregnancies and controls (**Table III**). Of the 9 studies reporting on HDL cholesterol in offspring blood, 7 were included in the meta-analysis, providing data on 7684 individuals, of whom 503 were exposed to preeclampsia in utero (**Figure 6**; available at




Figure 1. Study selection process. *CINAHL*, Cumulative Index to Nursing and Allied Health Literature.

www.jpeds.com). Quantitative summary measures obtained by meta-analysis did not demonstrate a significant difference in HDL cholesterol between offspring of preeclamptic pregnancies and controls (SMD 0.24, 95% CI -0.79 to 0.31 , **Figure 6**).^{11,15,16,21,25,27,39} Both studies that were not included in the meta-analysis reported that there was no significant difference in HDL levels in blood between the 2 groups (**Table III**).^{12,30}

Non-HDL Cholesterol


Non-HDL cholesterol data were available from 3 studies. Of these, 2 were included in the meta-analysis, providing data on 4058 individuals, of whom 306 were exposed to preeclampsia in utero (**Figure 7**; available at www.jpeds.com). Quantitative summary measures obtained by meta-analysis demonstrate no difference in non-HDL cholesterol between offspring of preeclamptic pregnancies compared with controls (SMD 0.06, 95% CI -0.07 to 0.18 , **Figure 7**).^{11,26} The study that was not included in the meta-analysis reports that offspring of term preeclamptic pregnancies have greater mean non-HDL cholesterol compared with controls but that no difference was observed among

offspring of preterm preeclamptic pregnancies compared with controls (**Table III**).¹²

Triglycerides

Triglyceride data were available from 13 studies, which included 6 on cord blood and 7 on offspring blood. Of the 6 studies on cord blood, 2 were included in the meta-analysis, providing data on 55 offspring from preeclamptic pregnancies and 51 controls. Quantitative summary measures obtained by meta-analysis demonstrate that offspring of preeclamptic pregnancies have greater cord blood triglyceride levels compared with controls (SMD 1.33, 95% CI -1.25 to 3.90 , **Figure 8** [available at www.jpeds.com]).^{21,33} Of the 4 studies that were not included in the meta-analysis, 2 report greater cord blood triglyceride levels in offspring of preeclamptic pregnancies^{10,13} and the other 2 report no difference between the 2 groups (**Table II**).^{36,44} Of the 7 studies reporting on offspring blood triglyceride levels, 4 were included in the meta-analysis, providing data on 1276 individuals of whom 216 were exposed to preeclampsia in utero. Quantitative summary measures obtained by


A Systolic Blood pressure



Footnotes

- (1) Female
- (2) Male
- (3) Female
- (4) Male

B Diastolic Blood pressure



Footnotes

- (1) Female
- (2) Male
- (3) Female
- (4) Male

Figure 2. A, Mean difference in SBP in mm Hg between those who were exposed to preeclampsia in utero and controls. **B,** Mean difference in DBP in mm Hg between those who were exposed to preeclampsia in utero and controls. *IV*, inverse variance.

meta-analysis demonstrate no difference in serum triglyceride levels between the 2 groups (SMD 0.05, 95% CI -0.13 to 0.23, **Figure 8**).^{15,27,28,39} Of the 4 studies that were not included in the meta-analyses, 3 report that serum triglyceride levels are not significantly different between the 2 groups (**Table III**).^{16,25,30} A study linking triglycerides in young adulthood with data from birth registries reports that offspring of term preeclamptic pregnancies have greater mean triglyceride levels but no difference between

offspring of preterm preeclamptic pregnancies and controls (**Table III**).¹²

Glucose

Fasting blood glucose data were available from 7 studies. Of these, 6 were included in the meta-analysis, providing data on 4334 individuals, of whom 486 were exposed to preeclampsia in utero (**Figure 9**; available at www.jpeds.com). Quantitative summary measures obtained by meta-analysis




Figure 3. Mean difference in BMI in kg/m² between those who were exposed to preeclampsia in utero and controls. PE, preeclampsia.

did not demonstrate a significant difference in blood glucose between offspring of preeclamptic pregnancies and controls (mean difference 0.01 mmol/L, 95% CI -0.03 to 0.05, **Figure 6**).^{11,15,16,27,28,39} The study that was not included in the meta-analysis reports that there is no difference in plasma glucose between the 2 groups (5.14 mmol/L [IQR 4.90, 5.50] vs 5.14 mmol/L [IQR 4.90, 5.40], **Table III**).³⁰

Insulin

Fasting insulin data were available from 6 studies. Of these, 4 were included in the meta-analysis, providing data on 1276 individuals, of whom 215 were exposed to preeclampsia in utero (**Figure 10**; available at www.jpeds.com). Quantitative summary measures obtained by meta-analysis demonstrate no difference in fasting insulin levels between the 2 groups (SMD 0.25, 95% CI -0.03 to 0.53, **Figure 10**).^{15,27,28,39} The 2 studies that were not included in the meta-analysis report no difference in plasma insulin between offspring of preeclamptic pregnancies and controls (**Table III**).^{16,30}

Vascular Function

Studies on umbilical cord and placenta have shown that cellular fibronectin (a marker of endothelial cell activation) is greater in cord blood of infants born of preeclamptic pregnancies compared with controls (*n* = 17 in each group, 3 ± 0.15 μg/mL vs 2.6 ± 0.14 μg/mL, *P* < .001) and that preeclampsia (*n* = 29) is associated with a smaller umbilical cord vein area and wall thickness compared with controls (*n* = 76).^{14,19} Studies on endothelial and cardiac function demonstrate smaller hearts, increased heart rates, and increased late diastolic velocity at the mitral valve at age 5-8 years, greater mean wall thickness (0.025; 95% CI

0.008-0.043), and smaller mean left ventricular end-diastolic volume (-9.0 mL; 95% CI -15 to -3.1) at age 17 years and 30% reduction in flow-mediated dilatation of the brachial artery at age 13-20 years (6.3 ± 1.2% vs 8.3 ± 1.4%, *P* < .0001) among those exposed to preeclampsia compared with controls.^{17,22,40} One study reported no difference in endothelial function at age 5-8 years between offspring of preeclamptic pregnancies compared with controls but a significant reduction in endothelial function in children of preeclamptic pregnancies who were also born small for gestational age compared with controls.²⁵

Discussion

This review demonstrates that offspring of preeclamptic pregnancies have greater SBP and DBP and a small increase in BMI, compared with controls. Our meta-analysis of 53 029 individuals of whom 1599 were exposed to preeclampsia in utero demonstrates a 5.17-mm Hg greater SBP among those exposed to preeclampsia compared with controls, and our meta-analyses of 52 993 individuals, of whom 1583 were exposed to preeclampsia in utero demonstrates a 4.06-mm Hg greater DBP among those exposed to preeclampsia compared with controls. The previous review by Davis et al reports a 2.39-mm Hg greater SBP (43 917 individuals, 1221 exposed to preeclampsia) and 1.35-mm Hg greater DBP (43 913 individuals, 1221 exposed to preeclampsia) among those exposed to preeclampsia in utero compared with controls.⁶ Our findings demonstrate a stronger association with the increase in sample size. Both SBP and DBP track from childhood to adulthood, with average reported tracking correlation being greater for SBP than for DBP.⁴⁹ Because elevated blood pressure in

childhood is proposed to help predict adult hypertension,⁴⁹ these findings warrant further investigation.

The previous review by Davis et al reported a 0.62 kg/m² increase in BMI among those exposed to preeclampsia compared with controls (39 473 individuals, 1062 exposed to preeclampsia).⁶ Consistent with the above, our current meta analyses, which includes 53 293 individuals, of whom 1752 were exposed to preeclampsia in utero, also demonstrates a small increase in BMI of 0.36 kg/m² among offspring of preeclamptic pregnancies compared with controls. Although commonly used, the accuracy of BMI as a predictor of adiposity in children is debatable. Among relatively fat children, BMI is shown to be a good indicator of excess adiposity, but the differences in BMI in relatively thin children can be largely due to fat-free mass.⁵⁰ A BMI for age or the BMI percentile of the Centers for Disease Control and Prevention reference population is considered a better predictor of adiposity among children.⁵⁰ The data on childhood adiposity using the aforementioned measures are limited for the populations relevant for this review and hence could not be assessed.

Our meta-analyses of studies on cord blood demonstrated greater LDL cholesterol and triglycerides and lower HDL cholesterol levels in offspring of preeclamptic pregnancies but no difference in offspring blood. The lack of translation of findings in cord blood to later years suggests that factors during pregnancy and labor including oxidative stress may influence the results in cord blood and that there is no difference in lipids between offspring of preeclamptic and control pregnancies.

The results on blood glucose and fasting insulin demonstrated no significant difference between offspring of preeclamptic pregnancies and controls. Two previous studies have assessed long-term risk for type 2 diabetes mellitus among offspring of preeclamptic pregnancies. The Helsinki birth cohort study of 5335 individuals reports that there is no association between the offspring risk for type 2 diabetes mellitus and maternal severe ($n = 134$) and nonsevere preeclampsia ($n = 97$) when offspring data were obtained at age 50–61 years.²³ Similar findings were reported in another study of 8648 individuals of whom 700 were exposed to preeclampsia in utero.²⁹ The results of fasting blood glucose and insulin levels found in our meta-analyses are consistent with the aforementioned findings that offspring of preeclamptic pregnancies are not at increased risk of developing type 2 diabetes mellitus compared with controls.

Only a limited number of studies have assessed vascular function in offspring of preeclamptic pregnancies. Therefore, we were not able to perform meta-meta-analysis on this variable. Although a few studies suggest that offspring of preeclamptic pregnancies show evidence of vascular dysfunction, current literature is not sufficient to draw conclusions on the effects if any of preeclampsia on offspring vascular health.

There are several potential limitations in our analyses that should be acknowledged. Both preeclampsia and CVD are multifactorial disorders with many genetic, environmental,

and lifestyle factors contributing to disease risk. The data available to us did not allow for detailed exploration of potential confounding factors. For example, a genetic link between preeclampsia and CVD is increasingly being discovered and hence, the association between preeclampsia and CVD risk factors in offspring could be due to shared genetic factors that contribute to both diseases.^{51–55} Another example is increased maternal BMI, which associates with increased risk of preeclampsia, offspring BMI, and offspring blood pressure, although the association with offspring blood pressure attenuates when childhood BMI is considered.^{43,56,57} There are also other confounders that have opposite effects on preeclampsia and CVD. Maternal smoking during pregnancy is associated with a 33% reduction in the risk of preeclampsia⁵⁸ but an increase in the risk of offspring blood pressure and BMI in adult life,⁵⁹ which could lead to an underestimation of the true effects of preeclampsia on offspring health. We considered the fact that observational studies are likely to be subject to publication bias and constructed funnel plots for all the outcome measures in meta-analyses and these were symmetrical. Meta-analysis of continuous outcome variables also is affected by heterogeneity among studies but our review did not demonstrate significant heterogeneity.

The finding of greater blood pressure among offspring of preeclamptic pregnancies warrants further review, since even a 2-mm Hg reduction in systolic blood pressure is shown to be associated with 10% lower mortality from stroke and 7% lower mortality from ischemic heart disease in middle age.⁶⁰ The studies eligible for this review do not report on the prevalence of hypertension requiring treatment or the prevalence of obesity among those exposed to preeclampsia in utero. Therefore, the finding of mild elevations in SBP, DBP, and BMI in the meta-analyses raises the question of clinical applicability of the findings.

At present, there is limited literature on this topic. However, a recent large population-based study of 231 298 deliveries between 1991 and 2014 compared cardiovascular risk factors among singletons exposed to preeclampsia in utero with those unexposed.⁶¹ In total, 4.1% of births in the cohort were to mothers diagnosed with preeclampsia, of whom 3.2% ($n = 7286$) had mild preeclampsia, 0.9% ($n = 2174$) had severe preeclampsia, and 0.03% ($n = 73$) had eclampsia. Cardiovascular risk was assessed in children up until 18 years of age. This study reports a significant linear relationship between the severity of preeclampsia and hypertension in the offspring. During the follow-up period, children exposed to mild preeclampsia, severe preeclampsia, and eclampsia had significantly greater rates of hypertension compared with children born after non-preeclamptic pregnancies (0.11%, 0.14%, and 1.37% vs 0.06%, $P < .001$) respectively. The prevalence of obesity showed a similar relationship with children exposed to mild preeclampsia, severe preeclampsia, and eclampsia having significantly greater rates of obesity compared with children born after non-preeclamptic pregnancies (0.4%, 0.4%, and 1.4% vs 0.2%, $P < .001$) respectively.⁶¹ Because elevated blood

pressure during childhood has been shown to predict the development of hypertension,⁴⁹ the findings of this meta-analysis support current literature and suggest that children born after preeclamptic pregnancies may benefit from routine blood pressure monitoring and targeted interventions when required. ■

Submitted for publication Aug 30, 2018; last revision received Nov 1, 2018; accepted Dec 5, 2018.

Reprint requests: Dr. Prabha H. Andraweera, Discipline of Obstetrics and Gynaecology, Adelaide Medical School and The Robinson Research Institute, The University of Adelaide, Adelaide, Australia. E-mail: prabha.andraweera@adelaide.edu.au

References

- McAloon CJ, Boylan LM, Hamborg T, Stallard N, Osman F, Lim PB, et al. The changing face of cardiovascular disease 2000-2012: an analysis of the world health organisation global health estimates data. *Int J Cardiol* 2016;224:256-64.
- Heida KY, Bots ML, de Groot CJ, van Dunne FM, Hammoud NM, Hoek A, et al. Cardiovascular risk management after reproductive and pregnancy-related disorders: a Dutch multidisciplinary evidence-based guideline. *Eur J Prev Cardiol* 2016;23:1863-79.
- Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* 2009;33:130-7.
- Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the american heart association. *Circulation* 2011;123:1243-62.
- Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ, Kajantie E, et al. Preeclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. *Stroke* 2009;40:1176-80.
- Davis EF, Lazdam M, Lewandowski AJ, Worton SA, Kelly B, Kenworthy Y, et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. *Pediatrics* 2012;129:e1552-61.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
- Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. *Pregnancy Hypertens* 2014;4:97-104.
- Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). *Hypertens Pregnancy* 2001;20:IX-XIV.
- Akcakus M, Altunay L, Yikilmaz A, Yazici C, Koklu E. The relationship between abdominal aortic intima-media thickness and lipid profile in neonates born to mothers with preeclampsia. *J Pediatr Endocrinol Metab* 2010;23:1143-9.
- Alsnes IV, Janszky I, Forman MR, Vatten LJ, Okland I. A population-based study of associations between preeclampsia and later cardiovascular risk factors. *Am J Obstet Gynecol* 2014;211:657.e1-7.
- Alsnes IV, Vatten LJ, Fraser A, Bjørngaard JH, Rich-Edwards J, Romundstad PR, et al. Hypertension in Pregnancy and Offspring Cardiovascular Risk in Young Adulthood: Prospective and Sibling Studies in the HUNT Study (Nord-Trøndelag Health Study) in Norway. *Hypertension* 2017;69:591-8.
- Catarino C, Rebelo I, Belo L, Rocha-Pereira P, Rocha S, Castro EB, et al. Fetal lipoprotein changes in preeclampsia. *Acta Obstet Gynecol Scand* 2008;87:628-34.
- Davidge ST, Signorella AP, Lykins DL, Gilmour CH, Roberts JM. Evidence of endothelial activation and endothelial activators in cord blood of infants of preeclamptic women. *Am J Obstet Gynecol* 1996;175:1301-6.
- Davis EF, Lewandowski AJ, Aye C, Williamson W, Boardman H, Huang RC, et al. Clinical cardiovascular risk during young adulthood in offspring of hypertensive pregnancies: insights from a 20-year prospective follow-up birth cohort. *BMJ Open* 2015;5:e008136.
- Fraser A, Nelson SM, MacDonald-Wallis C, Sattar N, Lawlor DA. Hypertensive disorders of pregnancy and cardiometabolic health in adolescent offspring. *Hypertension* 2013;62:614-20.
- Fugelseth D, Ramstad HB, Kvehaugen AS, Nestaa E, Støylen A, Staff AC. Myocardial function in offspring 5-8 years after pregnancy complicated by preeclampsia. *Early Hum Dev* 2011;87:531-5.
- Geelhoed JJ, Fraser A, Tilling K, Benfield L, Davey Smith G, Sattar N, et al. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon Longitudinal Study of Parents and Children. *Circulation* 2010;122:1192-9.
- Herzog EM, Eggink AJ, Reijnierse A, Kerkhof MAM, de Krijger RR, Roks AJM, et al. Impact of early- and late-onset preeclampsia on features of placental and newborn vascular health. *Placenta* 2017;49:72-9.
- Hiller JE, Crowther CA, Moore VA, Willson K, Robinson JS. Calcium supplementation in pregnancy and its impact on blood pressure in children and women: follow up of a randomised controlled trial. *Aust N Z J Obstet Gynaecol* 2007;47:115-21.
- Howlader MZ, Parveen S, Tamanna S, Khan TA, Begum F. Oxidative stress and antioxidant status in neonates born to pre-eclamptic mother. *J Trop Pediatr* 2009;55:363-7.
- Jayet PY, Rimoldi SF, Stuber T, Salmon CS, Hutter D, Rexhaj E, et al. Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. *Circulation* 2010;122:488-94.
- Kajantie E, Osmond C, Eriksson JG. Gestational hypertension is associated with increased risk of type 2 diabetes in adult offspring: the Helsinki Birth Cohort Study. *Am J Obstet Gynecol* 2017;216:281.e1-281.e7.
- Kvehaugen AS, Andersen LF, Staff AC. Anthropometry and cardiovascular risk factors in women and offspring after pregnancies complicated by preeclampsia or diabetes mellitus. *Acta Obstet Gynecol Scand* 2010;89:1478-85.
- Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. *Hypertension* 2011;58:63-9.
- Lawlor DA, Macdonald-Wallis C, Fraser A, Nelson SM, Hingorani A, Davey Smith G, et al. Cardiovascular biomarkers and vascular function during childhood in the offspring of mothers with hypertensive disorders of pregnancy: findings from the Avon Longitudinal Study of Parents and Children. *Eur Heart J* 2012;33:335-45.
- Lazdam M, de la Horra A, Pitcher A, Mannie Z, Diesch J, Trevitt C, et al. Elevated blood pressure in offspring born premature to hypertensive pregnancy: is endothelial dysfunction the underlying vascular mechanism? *Hypertension* 2010;56:159-65.
- Lazdam M, De La Horra A, Diesch J, Kenworthy Y, Davis E, Lewandowski AJ, et al. Unique blood pressure characteristics in mother and offspring after early onset preeclampsia. *Hypertension* 2012;60:1338-45.
- Libby G, Murphy DJ, McEwan NF, Greene SA, Forsyth JS, Chien PW, et al. Preeclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. *Diabetologia* 2007;50:523-30.
- Miettola S, Hartikainen AL, Väärämäki M, Bloigu A, Ruokonen A, Järvelin MR, et al. Offspring's blood pressure and metabolic phenotype after exposure to gestational hypertension in utero. *Eur J Epidemiol* 2013;28:87-98.
- Oglaend B, Forman MR, Romundstad PR, Nilsen ST, Vatten LJ. Blood pressure in early adolescence in the offspring of preeclamptic and normotensive pregnancies. *J Hypertens* 2009;27:2051-4.
- Oglaend B, Vatten LJ, Romundstad PR, Nilsen ST, Forman MR. Pubertal anthropometry in sons and daughters of women with preeclamptic or normotensive pregnancies. *Arch Dis Child* 2009;94:855-9.

33. Ophir E, Dourleshter G, Hirsh Y, Fait V, German L, Bornstein J. Newborns of preeclamptic women: a biochemical difference present in utero. *Acta Obstet Gynecol Scand* 2006;85:1172-8.
34. Palti H, Rothschild E. Blood pressure and growth at 6 years of age among offsprings of mothers with hypertension of pregnancy. *Early Hum Dev* 1989;19:263-9.
35. Reveret M, Boivin A, Guignonis V, Audibert F, Nuyt AM. Preeclampsia: effect on newborn blood pressure in the 3 days following preterm birth: a cohort study. *J Hum Hypertens* 2015;29:115-21.
36. Rodie VA, Caslake MJ, Stewart F, Sattar N, Ramsay JE, Greer IA, et al. Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by preeclampsia and intrauterine growth restriction. *Atherosclerosis* 2004;176:181-7.
37. Seidman DS, Laor A, Gale R, Stevenson DK, Mashiach S, Danon YL. Preeclampsia and offspring's blood pressure, cognitive ability and physical development at 17-years-of-age. *Br J Obstet Gynaecol* 1991;98:1009-14.
38. Staley JR, Bradley J, Silverwood RJ, Howe LD, Tilling K, Lawlor DA, et al. Associations of blood pressure in pregnancy with offspring blood pressure trajectories during childhood and adolescence: findings from a prospective study. *J Am Heart Assoc* 2015;4:e001422.
39. Tenhola S, Rahiala E, Martikainen A, Halonen P, Voutilainen R. Blood pressure, serum lipids, fasting insulin, and adrenal hormones in 12-year-old children born with maternal preeclampsia. *J Clin Endocrinol Metab* 2003;88:1217-22.
40. Timpka S, Macdonald-Wallis C, Hughes AD, Chaturvedi N, Franks PW, Lawlor DA, et al. Hypertensive disorders of pregnancy and offspring cardiac structure and function in adolescence. *J Am Heart Assoc* 2016;5:e003906.
41. Vatten LJ, Romundstad PR, Holmen TL, Hsieh CC, Trichopoulos D, Stuver SO. Intrauterine exposure to preeclampsia and adolescent blood pressure, body size, and age at menarche in female offspring. *Obstet Gynecol* 2003;101:529-33.
42. Washburn L, Nixon P, Russell G, Snively BM, O'Shea TM. Adiposity in adolescent offspring born prematurely to mothers with preeclampsia. *J Pediatr* 2013;162:912-7.
43. Wen X, Triche EW, Hogan JW, Shenassa ED, Buka SL. Prenatal factors for childhood blood pressure mediated by intrauterine and/or childhood growth? *Pediatrics* 2011;127:e713-21.
44. Yavuz T, Yavuz O, Ozdemir I, Afsar Y. Cord blood lipoprotein profile after magnesium sulphate treatment in preeclamptic patients. *Acta Paediatr* 2006;95:1224-7.
45. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M. Newcastle-Ottawa quality assessment scale. Ottawa Hospital Research Institute; 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed March 3, 2019.
46. Davis E, Lewandowski A, Aye C, Williamson W, Broadman H, Huang RC, et al. Evidence of hypertension but not metabolic disorders in young adults born to hypertensive pregnancies. *Heart* 2015;101:A83-4.
47. Akil A, Api O, Oten Can E, Ozkan S, Ercan S, Orcun A, et al. Does preeclampsia have any adverse effect on fetal heart? *J Matern Fetal Neonatal Med* 2016;29:2312-5.
48. Øglaend B, Forman MR, Romundstad PR, Nilsen ST, Vatten LJ. Blood pressure in early adolescence in the offspring of preeclamptic and normotensive pregnancies. *J Hypertens* 2009;27:2051-4.
49. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. *Circulation* 2008;117:3171-80.
50. Freedman DS, Sherry B. The validity of BMI as an indicator of body fatness and risk among children. *Pediatrics* 2009;124(suppl 1):S23-34.
51. Johnson MP, Brennecke SP, East CE, Dyer TD, Roten LT, Proffitt JM, et al. Genetic dissection of the pre-eclampsia susceptibility locus on chromosome 2q22 reveals shared novel risk factors for cardiovascular disease. *Mol Hum Reprod* 2013;19:423-37.
52. Andraweera PH, Dekker GA, Leemaqz S, McCowan L, Roberts CT. The obesity associated FTO gene variant and the risk of adverse pregnancy outcomes: evidence from the SCOPE study. *Obesity (Silver Spring)* 2016;24:2600-7.
53. Andraweera PH, Dekker GA, Thompson SD, North RA, McCowan LM, Roberts CT. A functional variant in ANGPT1 and the risk of pregnancies with hypertensive disorders and small-for-gestational-age infants. *Mol Hum Reprod* 2012;18:325-32.
54. Andraweera PH, Dekker GA, Thompson SD, Roberts CT. Single-nucleotide polymorphisms in the KDR gene in pregnancies complicated by gestational hypertensive disorders and small-for-gestational-age infants. *Reprod Sci* 2012;19:547-54.
55. Andraweera PH, Gattford KL, Dekker GA, Leemaqz S, Jayasekara RW, Dissanayake VHW, et al. The INSR rs2059806 single nucleotide polymorphism, a genetic risk factor for vascular and metabolic disease, associates with pre-eclampsia. *Reprod Biomed Online* 2017;34:392-8.
56. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *BMJ* 2005;330:565.
57. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. *N Engl J Med* 1997;337:869-73.
58. Wei J, Liu CX, Gong TT, Wu QJ, Wu L. Cigarette smoking during pregnancy and preeclampsia risk: a systematic review and meta-analysis of prospective studies. *Oncotarget* 2015;6:43667-78.
59. Power C, Atherton K, Thomas C. Maternal smoking in pregnancy, adult adiposity and other risk factors for cardiovascular disease. *Atherosclerosis* 2010;211:643-8.
60. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002;360:1903-13.
61. Nahum Sacks K, Friger M, Shoham-Vardi I, Spiegel E, Sergienko R, Landau D, et al. Prenatal exposure to preeclampsia as an independent risk factor for long-term cardiovascular morbidity of the offspring. *Pregnancy Hypertens* 2018;13:181-6.




Figure 4. SMD in total cholesterol between those who were exposed to preeclampsia in utero and controls.




Figure 5. SMD in LDL cholesterol between those who were exposed to preeclampsia in utero and controls.




Figure 6. SMD in HDL cholesterol between those who were exposed to preeclampsia in utero and controls.




Figure 7. Mean difference in non-HDL cholesterol between those who were exposed to preeclampsia in utero and controls.




Figure 8. SMD in triglycerides between those who were exposed to preeclampsia in utero and controls.





Figure 9. Mean difference in blood glucose in mmol/L between those who were exposed to preeclampsia in utero and controls.



Footnotes

- (1) Late PE
- (2) Early PE

Figure 10. SMD in fasting insulin levels between those who were exposed to preeclampsia in utero and controls.

Table II. Quality assessment using the adapted Newcastle–Ottawa Scale

| Manuscript | Selection | | | | Comparability | Exposure | | | Total score |
|-------------------------------------|-----------|----|----|----|---------------|----------|----|---|-------------|
| | 1 | 2 | 3 | 4 | | 1 | 2 | 3 | |
| Akcakus et al, 2010 ¹⁰ | | | | | | | | | N/A |
| Alsnes et al, 2014 ¹¹ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Alsnes et al, 2017 ¹² | a* | a* | b | a* | a+b** | a* | a* | b | 7 of 8 |
| Catarino et al, 2008 ¹³ | a* | a* | b | b | not cont | a* | a* | c | 4 of 8 |
| Davidge et al, 1996 ¹⁴ | a* | b | b | b | not cont | a* | b | c | 2 of 8 |
| Davis et al, 2015 ¹⁵ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Fraser et al, 2013 ¹⁶ | a* | a* | a* | b | a+b** | a* | a* | b | 7 of 8 |
| Fugelseth et al, 2011 ¹⁷ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Geelhoed et al, 2010 ¹⁸ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Herzog et al, 2017 ¹⁹ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Hiller et al, 2007 ²⁰ | c | a* | b | b | a+b** | b* | a* | b | 5 of 8 |
| Howlader et al, 2009 ²¹ | a* | a* | b | b | not cont | a* | a* | b | 4 of 8 |
| Jayet et al, 2010 ²² | a* | a* | c | b | not cont | a* | a* | c | 4 of 8 |
| Kajantie et al, 2009 ⁵ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Kajantie et al, 2017 ²³ | a* | a* | a* | b | a+b** | a* | a* | b | 7 of 8 |
| Kvehaugen et al, 2010 ²⁴ | c | b | b | b | not cont | a* | a* | c | 2 of 8 |
| Kvehaugen et al, 2011 ²⁵ | a* | a* | b | b | not cont | a* | a* | b | 4 of 8 |
| Lawlor et al, 2012 ²⁶ | a* | a* | b | b | not cont | a* | a* | b | 4 of 8 |
| Lazdam et al, 2010 ²⁷ | a* | b | b | a* | a+b** | a* | a* | c | 6 of 8 |
| Lazdam et al, 2012 ²⁸ | a* | b | a* | a* | not cont | a* | a* | c | 5 of 8 |
| Libby et al, 2007 ²⁹ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Miettola et al, 2013 ³⁰ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Ogland et al, 2009 ³¹ | a* | b | b | a* | a+b** | a* | a* | c | 6 of 8 |
| Ogland et al, 2017 | a* | a* | b | b | a* | a* | a* | b | 5 of 8 |
| Ophir et al, 2006 ³² | a* | a* | b | b | not cont | a* | a* | b | 4 of 8 |
| Palti et al, 1989 ³³ | a* | b | a* | a* | not cont | a* | a* | c | 5 of 8 |
| Reveret et al, 2015 ³⁴ | a* | a* | b | b | a* | a* | a* | b | 5 of 8 |
| Rodie et al, 2004 ³⁵ | a* | a* | b | b | a* | a* | a* | b | 5 of 8 |
| Seidman et al, 1991 ³⁶ | a* | b | c | b | a+b** | a* | b | c | 4 of 8 |
| Staley et al, 2015 ³⁷ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Tenhola et al, 2003 ³⁸ | a* | b | b | b | not cont | a* | b | c | 2 of 8 |
| Timpka et al, 2016 ³⁹ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Vatten et al, 2003 ⁴⁰ | | | | | | | | | N/A |
| Washburn et al, 2013 ⁴¹ | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Wen et al, 2011 ⁴² | a* | a* | b | b | a+b** | a* | a* | b | 6 of 8 |
| Yavuz, et al 2006 ⁴³ | a* | b | a* | b | not cont | e | a* | c | 3 of 8 |

N/A, not available; *not cont*, study does not control for any factor; * and **, A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

Table III. Results of studies not included in the meta-analyses

| Outcome and study | Age at follow-up, y | PE, n | Controls, n | PE results | Control results | P |
|-------------------------------------|---------------------|---------------------------------------|-------------|--|---|------------|
| SBP | | | | | | |
| Alsnes et al, 2017 ^{12*} | 29 | 343 term | 15 072 | +2.3 mm Hg (95% CI 1.1-3.5) | | |
| Lazdam et al, 2012 ²⁸ | 6 to 13 | 27 preterm 47 all (early and late) | | -0.6 mm Hg (95% CI -4.3 to 3.1) early PE vs late PE 96.27 ± 7.30 mm Hg vs 88.39 mm Hg ± 7.57 mm Hg | | .005 |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 116 mm Hg (IQR 108, 125) | 114 mm Hg (106, 123) | |
| Staley et al, 2015 ³⁷ | 7 | 161 | 6716 | 1.22 mm Hg (95% CI -0.52 to 2.97) | | |
| Wen et al, 2011 ⁴² | 7 | 30461 all | | 102.1 ± 10.4 mm Hg | 101.7 ± 10.1 mm Hg | |
| DBP | | | | | | |
| Alsnes et al, 2017 ^{12*} | 29 | 343 term | 15 072 | +1.0 mm Hg (95% CI 0.1-1.9) | | |
| | | 27 preterm | | 0.00 mm Hg (95% CI -2.1 to 2.2) | | |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 68 mm Hg (IQR 64, 74) | 67 mm Hg (62, 72) | |
| Staley et al, 2015 ³⁷ | 7 | 161 | 6716 | +0.49 mm Hg (95% CI -0.85 to 1.83) | | |
| BMI | | | | | | |
| Alsnes et al, 2017 ^{12*} | 29 | 343 term | 15 072 | 0.93 kg/m ² (95% CI 0.41-1.44) | | |
| | | 27 preterm | | mean difference -0.78 kg/m ² , 95% CI -2.05 to 0.49 | | |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 21.1 kg/m ² (IQR 19.0, 23.3) | 20.9 kg/m ² (IQR 18.9, 22.4) | |
| Timpka et al, 2016 ³⁹ | 12 | 42 | 1260 | 22.7 kg/m ² (IQR 19.9, 24.8) | 21.7 kg/m ² (IQR 19.9, 24.4) | |
| Total cholesterol | | | | | | |
| In cord blood | | | | | | |
| Catarino et al, 2008 ¹³ | At birth | 41 | 39 | 73 mg/dL (IQR 57, 97.5) | 86 mg/dL (IQR 72, 109) | .09 < .001 |
| Yavuz et al, 2006 ^{43†} | At birth | 7 | 26 | 65.0 mg/dL | 56.03 mg/dL | NS |
| In offspring blood | | | | | | |
| Kvehaugen et al, 2011 ²⁵ | 5-8 y | 19 | 14 | 5.01 mmol/L (IQR 4.44, 5.39) | 4.43 mmol/L (IQR 4.00, 5.00) | .04 |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 4.19 mmol/L (IQR 3.70, 4.70) | 4.19 mmol/L (IQR 3.70, 4.70) | |
| LDL cholesterol | | | | | | |
| In cord blood | | | | | | |
| Catarino et al, 2008 ¹³ | At birth | 41 | 39 | 34 mg/dL (IQR 28, 52) | 32 mg/dL (IQR 25, 50) | .68 |
| Yavuz et al, 2006 ^{43†} | At birth | 7 | 26 | 30.42 mg/dL | 25.53 mg/dL | NS |
| In offspring blood | | | | | | |
| Kvehaugen et al, 2011 ²⁵ | 5-8 y | 19 | 14 | 1.8 mmol/L (IQR 1.2, 2.4) | 0.3 | .04 |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 2.18 mmol/L (IQR 1.80, 2.60) | 2.17 mmol/L (IQR 1.90, 2.60) | |
| HDL in cord blood | | | | | | |
| Howlader et al, 2009 ²¹ | At birth | 15 | 20 | 10.33 ± 0.33 mg/dL | 13.34 ± 0.58 mg/dL | <.01 |
| Akcakus et al, 2010 ¹⁰ | At birth | 30 PE and 30 severe PE | 30 | PE 17.3 ± 12.3 mg/dL Severe PE 17.1 ± 12.8 mg/dL | 27.6 ± 13.0 mg/dL | .002 |
| Catarino et al, 2008 ¹³ | At birth | 41 | 39 | 32.0 mg/dL (IQR 25.5, 39.5) | 53 mg/dL (IQR 48, 57) | <.001 |
| Yavuz et al, 2006 ^{43†} | At birth | 7 | 26 | 28.28 mg/dL | 25.18 mg/dL | NS |
| Rodie et al, 2004 ³⁵ | At birth | 23 | 23 | 0.19 ± 0.12 mmol/L | 0.17 ± 0.09 mmol/L | .53 |
| HDL in blood | | | | | | |
| Alsnes et al, 2017 ^{12*} | 29 | 343 term | 15 072 | -0.01 (-0.05 to 0.02) mmol/L | | |
| | | 27 preterm | | -0.02 (-0.16 to 0.12) mmol/L | | |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 1.36 mmol/L (IQR 1.17, 1.62) | 1.38 mmol/L (IQR 1.20, 1.59) | .77 |
| Non-HDL cholesterol | | | | | | |
| Alsnes et al, 2017 ^{12*} | 29 | 343 term | 15 072 | 0.14 (95% CI 0.03-0.25) | | |
| | | 27 preterm | | 0.14 (95% CI -0.17 to 0.44) | | |

(continued)

Table III. Continued

| Outcome and study | Age at follow-up, y | PE, n | Controls, n | PE results | Control results | P |
|-------------------------------------|---------------------|------------------------|-------------|---|-------------------------------|-------|
| Triglycerides in cord blood | | | | | | |
| Akcakus et al, 2010 ¹⁰ | At birth | 30 PE and 30 severe PE | 30 | PE 39.2 ± 42.0 mg/dL Severe PE 39.5 ± 56.5 mg/dL | 14.9 ± 18.8 mg/dL | .039 |
| Catarino et al, 2008 ¹³ | At birth | 41 | 39 | 49.0 mg/dL (IQR 33.5, 63.5) | 39.0 mg/dL (IQR 29.0, 52.0) | <.001 |
| Rodie et al, 2004 ³⁵ | At birth | 23 | 23 | 0.50 ± 0.14 mmol/L | 0.44 ± 0.10 mmol/L | .09 |
| Yavuz et al, 2006 ^{43†} | At birth | 2 | 26 | 30.57 mg/dL | 32.57 mg/dL | NS |
| Triglycerides in blood | | | | | | |
| Fraser et al, 2013 ¹⁶ | 17 | 53 | 2404 | 0.7 mmol/L (IQR 0.6, 1.1) | 0.8 mmol/L (IQR 0.6, 1.0) | .56 |
| Kvehaugen et al, 2011 ²⁵ | 5-8 y | 19 | 14 | 0.60 mmol/L (IQR, 0.53, 0.73) | 0.58 mmol/L (IQR, 0.53, 0.82) | |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 0.75 mmol/L (IQR 0.56, 1.02) | 0.75 mmol/L (IQR 0.57, 0.97) | |
| Alsnes et al, 2017 ^{12*} | 29 | 343 term 27 preterm | 15 072 | 0.13 mmol/L (95% CI 0.06-0.21) (0.17 mmol/L, 95% CI -0.06 to 0.43) | | |
| Blood glucose | | | | | | |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 5.14 mmol/L (IQR 4.90, 5.50) | 5.14 mmol/L (IQR 4.90, 5.40) | |
| Insulin | | | | | | |
| Fraser et al, 2013 ¹⁶ | 17 | 53 | 2404 | 7.30 mU/L (IQR 5.3, 10.2) | 7.0 mU/L (IQR 5.1, 9.9) | |
| Miettola et al, 2013 ³⁰ | 16 | 174 | 4518 | 9.90 mU/L (IQR 7.30, 13.00) | 9.57 mU/L (IQR 7.30, 12.10) | |

*Results reported as mean difference compared with the control group.

†Results reported as median.